IMM News: Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study - 29th May 2023, 10:00pm

annb0t

Top 20
Immutep Limited

Media Release

Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause of multiple autoimmune diseases Charles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across...

>>> Read more: Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
 
Top Bottom